A new system has been developed for RNA-based drug screening, and the feasibility of this approach has been demonstrated by the identification of new immunomodulating compounds. Peripheral blood mononuclear cells were chosen as the cellular assay system. Cells were either stimulated by TPA/ionomycin to produce T cell cytokines as asthma targets or stimulated by lipopolysaccharide to produce proinflammatory cytokines as targets for chronic obstructive pulmonary disease (COPD). The authors developed a new fully automated system for RNA purification from cells grown in 96-well plates. Gene expression was determined in 384-well plates using real-time quantitative one-tube RT-PCR. Small interdonor variation could be demonstrated. The assay system was validated with known immunosuppressants cyclosporine and dexamethasone. Screening of 800 compounds resulted in 9.5% compounds inhibiting the induction of at least 1 T cell-derived cytokine and 6.8% compounds inhibiting at least 1 cytokine relevant for COPD. All these compounds were retested by analyzing remaining RNA from the 1st round of screening. The reproducibility of hits was between 56% and 74% for different cytokines. One compound selectively inhibited TNFα, which was confirmed by IC 50 determination. Analyzing its effect on cells from different donors revealed little interdonor variation. In conclusion, the authors established fully automated RNA isolation and precise gene expression profiling using real-time RT-PCR for drug screening. (Journal of Biomolecular Screening 2004:95-102) 
INTRODUCTION

P
ROGRESS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY dramatically influences research and development in the pharmaceutical industry by introducing new enzymes and receptors as drug targets. The advent of combinatorial chemistry to generate large libraries of molecules represents a great promise to revolutionize drug discovery. Lead compounds are identified by screening against relevant molecular targets. To achieve this approach, highly automated high-throughput screening (HTS) methods have been developed, which enable processing of a vast amount of screens and result in a large number of hits. 1 Asthma bronchiale is characterized by reversible airflow obstruction, bronchial hyperresponsiveness, with eosinophilic airway inflammation and tissue remodeling of the airway wall. 2 At present, inhaled corticosteroids, bronchodilators including ß 2 -adrenoceptor agonists, anticholinergics, xanthine derivatives, and leukotriene inhibitors are most effective and important drugs for the therapy of asthma. 3 But there are still some problems in the treatment of asthma by drugs available at present. The fact that asthma still causes considerable morbidity, mortality, and utilization of health care resources despite the widespread use of anti-inflammatory treatment suggests that new approaches are needed. 4 There is convincing evidence that allergen-specific CD4 + Th2 cells play a key role in allergic asthma. Th2 cells are a subtype of CD4+ T helper cells. These cells produce IL-4, IL-5, IL-10, und IL-13, which causes allergic reactions by the activation of eosinophils, production of IgE antibodies, and the sensibilization of mast cells. 5 Consequently, the inhibition or modulation of allergen-specific Th2 cells and their cytokines has become an attractive target for novel therapeutic intervention strategies in allergy. 6 The goal is the identification of small molecules, which inhibit Th2 cytokines selectively. In contrast to steroids, such drugs shall not affect Th1 cytokines.
Chronic obstructive pulmonary disease (COPD) is another severe disease of the airways. It is one of the leading causes of death and disability. In COPD, chronic inflammation results in fixed nar-rowing of small airways and alveolar wall destruction (emphysema). 7 This is characterized by increased numbers of alveolar macrophages, neutrophils, and cytotoxic T lymphocytes, and the release of multiple inflammatory mediators (lipids, chemokines, cytokines, growth factors). Unlike asthma, this inflammation appears to be resistant to corticosteroids, prompting the search for novel anti-inflammatory therapies that may prevent the relentless progression of the disease. 8 Primary cells of human origin are the most physiologically relevant model system. However, in general, primary cells cannot be obtained at the scale necessary for HTS. Our goal was to develop a cell-based screening, which by the use of PCR decreases the amount of cells needed so that primary cells could be used. We chose peripheral blood mononuclear cells (PBMC) as our cellular assay system. The T-lymphocyte population of this mixture can be stimulated to produce high amounts of Th1 and Th2 cytokines relevant for asthma. The monocyte fraction can be stimulated by lipopolysaccharide (LPS) to produce high amounts of cytokines relevant for COPD. In this study, we present the development of such a screening and demonstrate its feasibility by the identification of a compound selectively inhibiting TNFα.
MATERIALS AND METHODS
Reagents
Oligonucleotides were synthesized by TIB Molbiol (Berlin, Germany). DMSO, LPS, TPA, ionomycin, and Histopaque-1077 were from Sigma (Deisenhofen, Germany). Cyclosporine A (CsA) was from CALBIOCHEM (San Diego, CA, USA). RPMI 1640 medium was from Life Technologies (Heidelberg, Germany). Unless otherwise indicated, all other chemicals were purchased from the Sigma Chemical Co. (Deisenhofen, Germany).
Cell preparation and culture
PBMC were isolated from heparinized blood samples by density gradient centrifugation over Histopaque 1077 (Sigma), washed twice in Hanks buffer (Invitrogen, Heidelberg, Germany), and resuspended in RPMI 1640 (Invitrogen, Heidelberg, Germany) supplemented with 10% FCS (Roche, Penzberg, Germany). Viability was greater than 95% as determined by the trypan blue exclusion test. For cytokine production, PBMC from healthy volunteers were resuspended at 10 6 cells/ml and incubated in 100 µl aliquots in 96-well tissue culture plates (Falcon Becton Dickinson Labware, Heidelberg, Germany) at 37°C, 5% CO 2 . After preincubation with test substances for 30 min, cells were stimulated with phorbol ester (TPA) (25 ng/ml) plus ionomycin (1 µM) or LPS (1 µg/ml). At the indicated times, cells were sedimented by centrifugation, lysed by RLT lysis buffer (QIAGEN, Hilden, Germany), and frozen at -80°C until RNA isolation.
RNA preparation
Total RNA was isolated using the RNeasy 96 BioRobot 8000 kit (QIAGEN) and the BioRobot Gene Expression (QIAGEN). RNeasy 96 is based on selective binding of RNA to a silica-gelbased membrane under highly denaturing conditions with guanidinium isothiocyante. The lysis of the cells was performed manually, and the lysate was stored at -70°C until the RNA purification. All following purification steps have been performed on the BioRobot Gene Expression with a fully automated protocol. The automated procedure used in this investigation started with the addition of ethanol and transfer of the sample to the plate. After different washing steps and drying of the membrane, the pure RNA was eluted in RNase-free water and stored at -80°C until analysis. The worktable of the BioRobot Gene Expression includes a cooling and heating system; a robotic handling system, allowing walkaway processing by enabling the use of an automated vacuum manifold; and an 8-probe pipetting system as well as a high-speed dispensing system. The worktable has the capacity to purify RNA from up to 192 samples in 1 run. The purification time depends on using an optional DNase digest and is for 96 samples between 75 and 90 min.
Analysis of cytokine mRNA expression by real-time RT-PCR
One-tube RT-PCR was performed using QuantiTect Probe RT-PCR Kit™ (QIAGEN). Expression of cytokines were determined in relation to β-actin by real-time RT-PCR using TaqMan assays on an ABI Prism 7900. In preceding experiments, it was confirmed that actin is a suitable housekeeping gene by showing that its RNA level is not altered during stimulation. Primers and probes have already been described. 9 Quantity of mRNA was calculated using the ∆ ∆ C T method. 10 For each RT-PCR, the threshold cycle (C T ) was determined, being defined as the cycle at which the fluorescence exceeds 10 times the standard deviation of the mean baseline emission for cycles 3 to 10. Cytokine levels were normalized to the housekeeping gene ß-actin according to the following formula:
. Subsequently, respective cytokine mRNA levels were calculated using the ∆ ∆ C T method, that is, ∆ C T values representing mRNA from cells treated with stimulus in combination with a test compound were set in relation to the ∆ C T value representing mRNA levels from cells treated with stimulus alone according to the following formula:
The relative mRNA level for the respective test compound was calculated as 2 -∆ ∆ C T * 100% based on the results of control experiments, where an efficiency of the PCR reactions of approximately 100% was determined.
RESULTS
Interdonor variation of real-time RT-PCR assays
Stimulation of human PBMC by mitogenic stimuli was chosen as the cellular assay system. TPA and ionomycin are well-known mitogenic stimuli, which activate T cells maximally by activating protein kinase C and elevating intracellular calcium levels, respectively. LPS activates monocytes by binding to cell membrane receptor complexes. Cells from 6 different donors were stimulated with TPA/ionomycin or LPS. We chose Th1 cytokine IL2 and Th2 cytokines IL-4 and IL-13 as primary targets for asthma and IL-6, IL-8, and TNFα as primary targets for COPD. Figure 1a shows that TPA/ionomycin stimulated IL-2, IL-4, and IL-13 in PBMCs very potently. Correspondingly, LPS stimulated IL-6, IL-8, and TNFα (Fig. 1b) . By assaying mRNA using real-time RT-PCR, we observed very little donor-to-donor variation (Fig. 1) .
Screening
Ten different compound plates were prepared, each containing 80 different compounds. The 800 compounds, which were used in the screening assay, fulfill the 5 main criteria defined by Lipinski et al., 11 they are druglike, and they are reflecting the chemical diversity of a compound library comprising a total of 54,000 different chemical structures. Because most of these structures are proprietary, further details cannot be shown. Furthermore, 8 positive (stimulated and stimulated/vehicle treated) and 8 negative (without stimulation) controls were included. PBMCs were prepared from buffy coats, so that for each screening all assays were performed from the same batch of cells. PBMCs were seeded in 10 96-well plates and added to each well of each plate a compound from the corresponding compound plate. After 30 min, cells were stimulated for 4 h. Thereafter, cells were harvested, total cellular RNA prepared, and real-time RT-PCR performed. Two different screenings were performed. In the 1st screening, cells were stimulated by TPA/ionomycin and the transcript levels of ß-actin, IL-2, IL-4, and IL-13 were determined. In the 2nd screening, cells were stimulated by LPS and the transcript levels of ß-actin, IL-1ß, IL-6, and TNFα were determined. Table 1 shows the intraplate variability for each of the 10 different screening plates of 2 different screenings. For characterizing the reproducibility of the RT-PCR, the C.V. of ß-actin was calculated for all 96 wells per plate. The C.V. for ß-actin was between 2.43% and 4.37%. To determine the reproducibility of the assays, the variation in cytokine activity of vehicle-treated control wells from each of the 10 different compound plates was analyzed. Figure 2 shows the interplate variation for each assay. For the intraplate variation, the C.V. of cytokine activity for each plate was also calculated ( Table 1 ). The C.V. for IL-2, IL-4, and IL-13 assay was 10% to 68%, 21% to 52%, and 19% to 54%, respectively. The C.V. for IL-6, IL-8, and TNF assay was 7% to 53%, 12% to 61%, and 23% to 54%, respectively. The activity of the unstimulated controls was between 0% and 0.4% for all assays. The C.V. for all plates for the IL-2, IL-4, and IL-13 assay was 52%, 32%, and 38%, respectively. The corresponding Z-factors 12 were -0.56, 0.04, and -0.14, respectively. The C.V. for the complete screening for IL-6, IL-8, and TNF assay was 27%, 32%, and 37%, respectively. The corresponding Z-factors were 0.19, 0.04, and -0.11, respectively. The C.V.s were used to determine the cutoff value for the identification of compounds in our screening as hits. Because for some assays the C.V. was rather large, we defined a compound as a hit by causing at least 75% inhibition in one cytokine assay.
Reproducibility and determination of cutoff
FIG. 1.
Donor variability. PBMCs were prepared from six different donors. Cells were stimulated with TPA (25 ng/ml)/ionomycin (1 µM) (A) or LPS (1 µg/ml) (B). After 4 h, cells were harvested and RNA prepared. Cytokine mRNA levels were determined using real-time RT-PCR and were normalized to ß-actin. Bars represent means ± s.e.m. of 6 different donors.
A B
Validation with known immunomodulating compounds
The screening system was validated with well-characterized reference compounds and determined their IC 50 . First, we analyzed the dose response of CsA on IL-2 induced by stimulation with TPA/ionomycin. CsA inhibited mRNA induction in the low nanomolar range with an IC 50 of 2.2nM (Fig. 3a) . Dexamethasone inhibited LPS-induced IL-1ß with an IC 50 of 2.8 nM (Fig. 3b) .
Screening results
We performed 2 different screenings. In the 1st screening, cells were stimulated by TPA/ionomycin. The transcript levels of ß-actin, IL-2, IL-4, and IL-13 were determined. Of 800 compounds, 76 (9.5%) inhibited the induction of at least one cytokine (Table 2 ). In the 2nd screening, cells were stimulated by LPS. The transcript levels of ß-actin, IL-1ß, IL-6, and TNFα were determined. Of 800 compounds, 54 (6.8%) inhibited the induction of at least one cytokine. In addition, 11 compounds inhibited all cytokines in both screenings. These compounds were not considered further, because we suspected unspecific action and we were interested in more selective inhibitors. All other compounds, which inhibited at least one cytokine, were retested. For IL-2, IL-4, and IL-13, the reproducibility of hits was 74%, 59%, and 72%, respectively. For TNFα, IL-6, and IL-8 the reproducibility of hits was 56%, 74%, and 57%, respectively.
Determination of IC 50
One hit, which was identified by selectively inhibiting TNFα, was selected for determination of IC 50 . A dilution series of this compound was tested on LPS-stimulated PBMCs. This compound Ten different compound plates were used for 2 different drug screenings. First screening used stimulation by TPA/ionomycin, 2nd screening used LPS stimulation. Of each plate, RNA was prepared and ß-actin and cytokines were determined for each well using realtime RT-PCR. The C.V. of ß-actin C t values of 96 wells for each plate were calculated. From each of the 10 different compound plates the C.V. of cytokine activity of 4 vehicletreated wells for each plate was calculated. IL-2, IL-4, and IL-13 were determined for the 1st screening, TNFα, IL-6, and IL-8 were determined for the 2nd screening.
FIG. 2.
Assay variability. From each of the 10 different compound plates, vehicle-treated control wells were analyzed. IL-2, IL-4, and IL-13 were determined for the 1st screening (A); TNFα, IL-6, and IL-8 were determined for the 2nd screening (B). Cytokine mRNA level were determined using real-time RT-PCR and were normalized to ß-actin. Mean of all stimulated and vehicle-treated wells was used as 100%.
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selectively inhibited TNFα after LPS stimulation, whereas IL-6 and IL-8 were hardly affected even at highest concentrations. The IC 50 for TNFα mRNA was 2.2 µM. Furthermore, we determined the variability for cells from different donors. The dose response curves for 3 different donors for this compound looked very similar (Fig. 4) . The IC 50 was calculated to be 2.2 µM, 2.8 µM, and 2.2 µM, respectively.
DISCUSSION
Today drug-screening assays are shifting from isolated targets toward living cell analysis, because cells represent the ultimate target for drugs and a source of a new level of biological knowledge. Using cell-based assays earlier in the screening cascade can provide better quality leads and reduce lead failure at later stages. Such assays yield data with enriched bio-information content and can be used to identify leads from hits. This study presents a new screening method generating such information-enriched compound profiles.
No currently available drug therapy reduces the progression of COPD, and there is a pressing need to develop new drugs that control the underlying inflammatory and destructive processes. 8 Medication used for asthma did not change significantly during the last years. Steroids remain the mainstay of the anti-inflammatory part of asthma therapy. Unwanted side effects of steroids demonstrate the need for new anti-inflammatory drugs for asthma therapy. 4 We evaluated our screening system by searching for new compounds aimed at key cytokines involved in the pathogenesis of asthma and COPD.
Primary cells of human origin are arguably the most physiologically relevant model system. However, in general, primary cells cannot be obtained at the scale necessary for HTS, and thus primary cell screens are positioned in the screening paradigm as lowthroughput secondary assays. By using real-time RT-PCR as a readout, we were able to decrease the amount of cells necessary for 1 assay substantially. We used 1 × 10 5 cells per well, which yielded usually 1-2 µg of total RNA. By using 50 ng of total RNA per PCR reaction, we could show that 1 × 10 5 cells per assay yield an amount of RNA sufficient for at least 30 PCR reactions. From a buffy coat from 1 volunteer, which yields around 5 × 10 8 cells, a sufficient number of cells for 5000 assays can be prepared. Therefore, much fewer cells are required per assay as for other cell-based assays, for example, ELISA or reporter gene assays using 5 to 10 × 10 5 cells per assay. 13 Furthermore, by using 50 ng per PCR reaction, we did not reach the detection limit of the RT-PCR for our genes of interest. Due to the high sensitivity of RT-PCR and the large dynamic range of real-time RT-PCR, it may be possible to further decrease the necessary number of cells per assay. This would yield much more assays from the same batch of cells. By combining 96-well cell culture, fully automated total cellular RNA isolation and 384-well real-time RT-PCR, we established a new screening method assaying gene expression changes as the response of primary cells to compound libraries.
We stimulated PBMCs with mitogens to induce cytokines, which have been found to be increased during the inflammation of either asthma or COPD. Interdonor variation was found to be low enough to enable the reliable identification of hit compounds. The C.V. for the RT-PCR assay itself is very low. However, the C.V. for the different cytokine assays is substantially higher. This can be explained by 2 reasons. First, for activity calculation, 4 different C t - values have to be taken into account: the actin and the cytokine C tvalue of the control and of the sample (for details of activity calculation, see methods). By this, the error of 4 RT-PCRs influences the assay activity. Second, due to the exponential amplification during the PCR, small errors amplify also exponentially. Duplicate measurements of individual samples would reduce Z-factors significantly.
RNA-Based Drug
First we validated the screening method with well-known immunosuppressants. The IC 50 s for CsA and dexamethasone are in agreement with previously published data. 14, 15 Therefore, this screening proved to be effective for the identification of immunomodulating compounds. A small compound library of 800 different substances was used for the evaluation of this system. The variation of the control samples was used to calculate cutoff values for the reliable identification of hit compounds. The hit rate for compounds targeting asthma-relevant cytokines was 9.5%, whereas the hit rate for compounds targeting COPD-relevant cytokines was 6.8%. Eleven compounds inhibiting all cytokines in both screenings were suspected of unspecific action. This was corroborated by the observation of decreased ß-actin mRNA level. These hit rates are higher than those observed for screening against isolated targets (T. Hage, unpublished observation). This may be explained by the fact that this screening identifies hit compounds by an endpoint assay such as mRNA determination. Since the mRNA is induced by surface receptor stimulation, all steps of the signal transduction cascade from the receptor to the mRNA induction are possible targets in this screening. This multiplication of targets may be the reason for the increased hit rate compared to single-target assays.
One important advantage of this screening method is the establishment of an RNA library. Due to the high sensitivity of RT-PCR, only a part of the RNA prepared from each sample is needed for primary screening. Therefore, after screening, a sufficient amount of RNA is left for immediate repeating RT-PCR analysis or extending analysis to further parameters. This is possible without new cell preparation, short-term culturing, and RNA preparation. Furthermore, the whole RNA library can be stored and used for testing other gene expression parameters in the future. RNA prepared by this method can be stored for at least 12 months at -80°C (S. Ullmann, unpublished observation). Longer storage periods are under investigation. Alternatively, the mRNA fraction in all total RNA library samples can be converted into cDNA and subsequently stored as a free cDNA library. In the future, targeting the expression of other genes may be of interest. In that case, only the RNA or cDNA library needs to be thawed and quantitative RT-PCR to be performed. No cell culture or other purification steps are needed. Because establishing new RT-PCR assays is a matter of days, this new screening can be done at a minimum amount of time and labor. No tedious steps like cloning of reporter constructs and establishing a stable reporter cell line or the production of antibodies for ELISA formats are necessary.
TNFα levels are raised in the sputum of COPD patients, 16 and TNFα induces IL-8 in airway cells via activation of the transcription factor NF-κB. 17 Humanized monoclonal TNFα antibodies (infliximab) and soluble TNFα receptors (etanercept) effective in other chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, should also be effective in COPD. 8 However, current therapeutics such as recombinant proteins or antibodies, are very expensive and laborious to produce. Therefore, great interest has been raised in small molecule compounds selectively inhibiting TNFα. Using our newly developed screening system, we were able to identify such a compound. 
